Therapeutic apheresis (TA) is a complex extracorporeal procedure for the treatment of several acute and chronic diseases. TA in pregnancy is considered safe for both mother and fetus and has the same indications of non-pregnant patients. TA can be used during the entire course of the pregnancy with the following purposes: (i) to treat several maternal acute and chronic conditions; (ii) to treat fetal conditions; (iii) to avoid administration of drugs potentially harmful to the fetus; and (iv) to reach a more advanced gestational age in order to prevent fetal prematurity. We report three successfully treated patients throughout pregnancy, for differential indications: thrombotic thrombocytopenic purpura, red blood cells alloimmunization and ulcerative colitis. Multiple courses of TA have been performed without any complications for the mother and the fetus. A review and a discussion on the particular TA implications related to maternal-fetal medicine have been reported. When approaching TA in pregnancy, clinicians have to consider the severity of disease, the strength of the indications, and the gestational age. Each case must be evaluated individually on the basis of existing evidence since, despite the increasing use, specific guidelines for apheresis in pregnancy are still lacking.

Therapeutic apheresis in pregnancy: three differential indications with positive maternal and fetal outcome / Perrone, Giuseppina; Brunelli, Roberto; Marcoccia, Eleonora; Zannini, Ilaria; Candelieri, Miriam; Gozzer, Maria; Stefanutti, Claudia. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - ELETTRONICO. - 20:6(2016), pp. 677-685. [10.1111/1744-9987.12422]

Therapeutic apheresis in pregnancy: three differential indications with positive maternal and fetal outcome

PERRONE, Giuseppina;BRUNELLI, Roberto;MARCOCCIA, ELEONORA;ZANNINI, ILARIA;CANDELIERI, MIRIAM
;
STEFANUTTI, Claudia
2016

Abstract

Therapeutic apheresis (TA) is a complex extracorporeal procedure for the treatment of several acute and chronic diseases. TA in pregnancy is considered safe for both mother and fetus and has the same indications of non-pregnant patients. TA can be used during the entire course of the pregnancy with the following purposes: (i) to treat several maternal acute and chronic conditions; (ii) to treat fetal conditions; (iii) to avoid administration of drugs potentially harmful to the fetus; and (iv) to reach a more advanced gestational age in order to prevent fetal prematurity. We report three successfully treated patients throughout pregnancy, for differential indications: thrombotic thrombocytopenic purpura, red blood cells alloimmunization and ulcerative colitis. Multiple courses of TA have been performed without any complications for the mother and the fetus. A review and a discussion on the particular TA implications related to maternal-fetal medicine have been reported. When approaching TA in pregnancy, clinicians have to consider the severity of disease, the strength of the indications, and the gestational age. Each case must be evaluated individually on the basis of existing evidence since, despite the increasing use, specific guidelines for apheresis in pregnancy are still lacking.
2016
pregnancy; red cell alloimmunization; therapeutic apheresis; thrombotic thrombocytopenic purpura; ulcerative colitis
01 Pubblicazione su rivista::01a Articolo in rivista
Therapeutic apheresis in pregnancy: three differential indications with positive maternal and fetal outcome / Perrone, Giuseppina; Brunelli, Roberto; Marcoccia, Eleonora; Zannini, Ilaria; Candelieri, Miriam; Gozzer, Maria; Stefanutti, Claudia. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - ELETTRONICO. - 20:6(2016), pp. 677-685. [10.1111/1744-9987.12422]
File allegati a questo prodotto
File Dimensione Formato  
Perrone_Therapeutic-apheresis_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 331.92 kB
Formato Adobe PDF
331.92 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/905011
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact